PD-1/CTLA-4 (Phio Pharma)

N/A

Report date: 2025/02/27 11:35:23
NME

Base Information

Drug NamePD-1/CTLA-4 (Phio Pharma)
Drug Alias NameN/A
ClassificationSmall molecules > Nucleosides and nucleotide derivtives > Oligonucleotide > Small Interfering RNA
Mechanisms of ActionProgrammed cell death protein 1 inhibitorsCytotoxic T-Lymphocyte-Associated Antigen 4 inhibitors
TargetsProgrammed cell death protein 1Cytotoxic T-Lymphocyte-Associated Antigen 4
Therapy Area/IndicationsNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesPhio Pharmaceuticals Corp
China Registration ClassN/A

Develop Information

Active CompaniesPhio Pharmaceuticals Corp
Inactive CompaniesN/A
Active IndicationsNeoplasms
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A